Department of Respiratory Diseases, Hospital São Lucas da Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil.
Ann Thorac Med. 2013 Jul;8(3):142-7. doi: 10.4103/1817-1737.114297.
There are reports of greater survival rates in nonsmall cell lung cancer (NSCLC) patients of female gender. The objective of this study was to evaluate the role of gender in survival of NSCLC patients treated surgically with curative intent (stage I/II).
In a retrospective cohort design, we screened 498 NSCLC patients submitted to thoracotomies at the hospital Sγo Lucas, in Porto Alegre, Brazil from 1990 to 2009. After exclusion of patients that did not fit to all the inclusion criteria, we analyzed survival rates of 385 subjects. Survival was analyzed using the Kaplan-Meier method. The Cox regression model was used to evaluate potential confounding factors.
Survival rates at 5 and 10 years were 65.3% and 49.5% for women and 46.5% and 33.2% for men, respectively (P = 0.006). Considering only stage I patients, the survival rates at 5 and 10 years were 76.2% and 55.1% for women and 50.7% and 35.4% for men, respectively (P = 0.011). No significant differences in survival rates were found among stage II patients.
Our results show female gender as a possible protective factor for better survival of stage I NSCLC patients, but not among stage II patients. This study adds data to the knowledge that combined both genders survival rates for NSCLC is not an adequate prognosis.
有报道称,女性非小细胞肺癌(NSCLC)患者的生存率更高。本研究旨在评估性别在接受根治性手术治疗的 NSCLC 患者(I/II 期)生存中的作用。
采用回顾性队列设计,我们筛选了 1990 年至 2009 年在巴西阿雷格里港 Sγo Lucas 医院接受开胸手术的 498 例 NSCLC 患者。排除不符合所有纳入标准的患者后,我们分析了 385 例患者的生存率。采用 Kaplan-Meier 法分析生存情况。Cox 回归模型用于评估潜在的混杂因素。
女性患者的 5 年和 10 年生存率分别为 65.3%和 49.5%,男性患者的 5 年和 10 年生存率分别为 46.5%和 33.2%(P=0.006)。仅考虑 I 期患者,女性患者的 5 年和 10 年生存率分别为 76.2%和 55.1%,男性患者的 5 年和 10 年生存率分别为 50.7%和 35.4%(P=0.011)。II 期患者的生存率无显著差异。
我们的结果表明,女性性别可能是 I 期 NSCLC 患者更好生存的保护因素,但在 II 期患者中并非如此。这项研究增加了数据,表明将 NSCLC 患者的生存率进行性别合并并不能作为一个充分的预后指标。